JP2016518379A - Obフォールド変異体を含む局所用組成物 - Google Patents
Obフォールド変異体を含む局所用組成物 Download PDFInfo
- Publication number
- JP2016518379A JP2016518379A JP2016509434A JP2016509434A JP2016518379A JP 2016518379 A JP2016518379 A JP 2016518379A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A JP2016518379 A JP 2016518379A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- skin
- protein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Abstract
Description
使用する試験は、フランツセル拡散試験である。
3匹のオスのウサギ(Fauve de Bourgogne)を用いた。
・100μlの液体をドナー側から採取し、交換は行わなかった。
目的:
nanofitinの皮膚透過性、およびその特性、特に、受容体-リガンドの関連性を中和する特性の保持を立証するために、乾癬タイプの炎症モデルを用いて、抗炎症性nanofitinの直接皮膚への局所投与後の炎症の低下(PASIスコア)を測定した。
マウスの耳の内面へのイミキモド(Aldara)の局所適用は、乾癬に似た皮膚炎症を引き起こす(Van der Fits et al., J Immunol. 2009 May 1;182(9):5836-45, Flutter et al., Eur J Immunol. 2013 Dec; 43(12):3138-46)。このプロトコールを6〜8週齢のBalb/cマウスの両耳に適用した。
− マウスがイミキモドを受けていない、対照群(負の対照)。
− マウスが両耳にイミキモドを受けかつ右耳には処置も受けている3つの実験群。これら3つの実験群は以下の通りである:
・nanofitin有効性試験群:この群の各実験サブグループに対して4種類の異なるnanofitinをマウス(n=4)の右耳に適用した。nanofitinは、任意で20%EtOHを有するPBSで製剤化された。
・マウスが処置した耳にnanofitin担体だけ(PBS、20% EtOH)を受けている対照群。
・マウスが処置の正の対照として対照処置(クロベタゾール)を局所的に受けている、対照群。
− 連続して7日間、朝に1投与/日でイミキモドの連日投与。
− 3日目から始めて7日目まで、夜に1投与/日でnanofitinまたはその他の対照の投与。
− 4日目から7日目まで、朝、イミキモド投与前に、PASIスコアの観察および判定。
− 8日目、PASIスコアの判定後に屠殺。
適用した全てのnanofitinについて、未処置の耳と比べて、処置した耳で炎症の非常に有意な減少が見られた(図1)。未処置の耳の炎症は、クロベタゾールを受けている群を除き、どの群でも維持された。
抗炎症性nanofitinの局所投与は、処置5日後の炎症症状の30%を上回る、おそらく80%を超える低下を引き起こすことを可能にした。
Claims (10)
- 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を含む、局所用組成物。
- 前記野生型OBフォールドタンパク質が、スルホロブス・アシドカルダリウス(Sulfolobus acidocaldarius)由来のSac7dまたはSac7e、スルホロブス・ソルファタリカス(Sulfolobus solfataricus)由来のSso7d、スルホロブス・トコダイイ(Sulfolobus tokodaii)由来のDBP 7、スルホロブス・シバタエ(Sulfolobus shibatae)由来のSsh7b、スルホロブス・シバタエ由来のSsh7a、およびスルホロブス・ソルファタリカス由来のp7ssから選択されることを特徴とする、請求項1記載の組成物。
- 10 mg/mlから600 mg/mlの前記変異体を含有することを特徴とする、請求項1および2のいずれか一項記載の組成物。
- 前記変異体が、抗原、抗体、細胞タンパク質、循環タンパク質、ペプチド、薬剤の活性成分、核酸、および特にインターロイキン、サイトカイン、サイトカインまたはインターロイキンの受容体、癌遺伝子によりコードされるタンパク質、微生物の表面タンパク質、ならびに微生物リポ多糖から選択される対象の標的に結合することを特徴とする、請求項1から3のいずれか一項記載の組成物。
- 皮膚に適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
- 眼レベルで適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
- 水性、油性もしくは水性-アルコール性溶液、エマルジョン、マイクロエマルジョン、水性ゲル、無水ゲル、血清、小胞分散系、ローション、ゲル、クリーム、泡、エアロゾルまたはスプレーの形態にあることを特徴とする、請求項1から6のいずれか一項記載の組成物。
- 抗菌剤、抗寄生虫剤、抗真菌剤、抗炎症剤、鎮痒剤、麻酔剤、抗ウイルス剤、角質溶解剤、フリーラジカルスカベンジャー、抗脂漏剤、フケ防止剤、および抗ニキビ剤、ならびに皮膚の分化および/または増殖および/または色素沈着を調節するための作用物質から選択される少なくとも1つの作用物質も含有することを特徴とする、請求項1から7のいずれか一項記載の組成物。
- 皮膚または眼の障害または疾患の処置における使用のための、請求項1から8のいずれか一項記載の局所用組成物。
- 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を薬学的にまたは化粧用に許容される担体と混合する段階を含む、請求項1から9のいずれか一項記載の局所用組成物を調製するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR13/53662 | 2013-04-22 | ||
FR1353662A FR3004650B1 (fr) | 2013-04-22 | 2013-04-22 | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
PCT/EP2014/058139 WO2014173899A1 (fr) | 2013-04-22 | 2014-04-22 | Compositions topiques comprenant des variantes de pli-ob |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019022358A Division JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016518379A true JP2016518379A (ja) | 2016-06-23 |
JP2016518379A5 JP2016518379A5 (ja) | 2017-06-15 |
Family
ID=48795734
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509434A Pending JP2016518379A (ja) | 2013-04-22 | 2014-04-22 | Obフォールド変異体を含む局所用組成物 |
JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10548945B2 (ja) |
EP (1) | EP2988766B1 (ja) |
JP (2) | JP2016518379A (ja) |
CN (2) | CN105338995B (ja) |
ES (1) | ES2637421T3 (ja) |
FR (1) | FR3004650B1 (ja) |
WO (1) | WO2014173899A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021502823A (ja) * | 2017-11-14 | 2021-02-04 | アフィロジック | 多重特異性分子 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
EP3632924A1 (en) | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
US11597751B2 (en) | 2019-05-16 | 2023-03-07 | Massachusetts Institute Of Technology | Glycan-binding proteins and related compositions and methods |
EP3878858A1 (en) | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
EP4043481A1 (en) | 2021-02-15 | 2022-08-17 | Affilogic | Compounds and methods for extending half life of biomolecules |
EP4308590A1 (en) | 2021-03-18 | 2024-01-24 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
EP4059949A1 (en) | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
CN116004564B (zh) * | 2022-06-01 | 2023-08-18 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010511691A (ja) * | 2006-12-04 | 2010-04-15 | インスティティ・パスツール | 新たな特異的結合体を工学的に操作するための足場として使用されるob−フォールド |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228616A1 (en) * | 1999-10-29 | 2003-12-11 | Stratagene | DNA polymerase mutants with reverse transcriptase activity |
NZ573407A (en) * | 2006-05-26 | 2012-09-28 | Obodies Ltd | Ob fold domains |
EP2358746B1 (en) * | 2008-11-03 | 2020-09-16 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
EP2469278A1 (en) * | 2010-12-21 | 2012-06-27 | Institut Pasteur | Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use |
FR2974816A1 (fr) * | 2011-05-04 | 2012-11-09 | Centre Nat Rech Scient | Methode de generation de proteines |
FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
WO2018048941A2 (en) * | 2016-09-08 | 2018-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue |
EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
EP3632924A1 (en) * | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
-
2013
- 2013-04-22 FR FR1353662A patent/FR3004650B1/fr not_active Expired - Fee Related
-
2014
- 2014-04-22 CN CN201480030115.3A patent/CN105338995B/zh active Active
- 2014-04-22 EP EP14718621.7A patent/EP2988766B1/fr active Active
- 2014-04-22 WO PCT/EP2014/058139 patent/WO2014173899A1/fr active Application Filing
- 2014-04-22 US US14/786,287 patent/US10548945B2/en active Active
- 2014-04-22 JP JP2016509434A patent/JP2016518379A/ja active Pending
- 2014-04-22 CN CN202010402321.XA patent/CN111467477A/zh active Pending
- 2014-04-22 ES ES14718621.7T patent/ES2637421T3/es active Active
-
2019
- 2019-02-12 JP JP2019022358A patent/JP2019112410A/ja active Pending
- 2019-12-24 US US16/726,305 patent/US10898542B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010511691A (ja) * | 2006-12-04 | 2010-04-15 | インスティティ・パスツール | 新たな特異的結合体を工学的に操作するための足場として使用されるob−フォールド |
Non-Patent Citations (3)
Title |
---|
MEMBRANE, vol. 36, no. 4, JPN6019017366, 2011, pages 139 - 144, ISSN: 0004034783 * |
PLOS ONE, JPN6019017365, 2015, pages 1 - 17, ISSN: 0004034782 * |
日経バイオテクONLINE, vol. [平成29年12月18日検索], JPN6017049770, February 2013 (2013-02-01), ISSN: 0004034781 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021502823A (ja) * | 2017-11-14 | 2021-02-04 | アフィロジック | 多重特異性分子 |
Also Published As
Publication number | Publication date |
---|---|
EP2988766A1 (fr) | 2016-03-02 |
US20200138899A1 (en) | 2020-05-07 |
CN111467477A (zh) | 2020-07-31 |
US20160143990A1 (en) | 2016-05-26 |
FR3004650A1 (fr) | 2014-10-24 |
ES2637421T3 (es) | 2017-10-13 |
FR3004650B1 (fr) | 2015-05-29 |
US10548945B2 (en) | 2020-02-04 |
US10898542B2 (en) | 2021-01-26 |
CN105338995B (zh) | 2020-06-09 |
CN105338995A (zh) | 2016-02-17 |
JP2019112410A (ja) | 2019-07-11 |
EP2988766B1 (fr) | 2017-06-07 |
WO2014173899A1 (fr) | 2014-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10898542B2 (en) | Topical compositions comprising OB-fold variants | |
KR20160113121A (ko) | 핵산 제조 및 송달을 위한 방법 및 산물 | |
KR20130139254A (ko) | 피부 침투 및 세포 진입(space) 펩타이드 및 그의 사용방법 | |
KR101397912B1 (ko) | 여드름 및 기타 질환 치료용 비스파틴 치료제 | |
Papa et al. | Functionalized nanogel for treating activated astrocytes in spinal cord injury | |
Dubey et al. | Noninvasive transdermal iontophoretic delivery of biologically active human basic fibroblast growth factor | |
EP3808762A1 (en) | Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients | |
CN106456542A (zh) | 用于局部递送的适体 | |
CN112135636A (zh) | 含有核酸复合物的皮肤渗透载体及其用途 | |
Zhao et al. | Ionic liquid-enabled topical delivery of immunomodulators | |
EP2958572B1 (en) | Treatment of hyperhidrosis | |
KR20200052828A (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
WO2015086830A1 (en) | Skin penetrating polypeptides | |
WO2019047299A1 (zh) | 具有核定位能力的透皮短肽及其应用 | |
CN110669143B (zh) | 一种短肽及其应用 | |
US20190030186A1 (en) | Use of bacterial voltage gated ion channels for human therapies | |
CN113501862A (zh) | 一种多肽及其在制备免疫调节药物中的应用 | |
TWI769208B (zh) | Snap25反義寡核苷酸 | |
US20040151739A1 (en) | Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages | |
EP1334195B1 (de) | Analoga, agonisten, antagonisten und varianten der oxidoreduktase-enzymaktivität des makrophagen-migrations-inhibitions-faktors (mif) als immunmodulatoren, therapeutika, diagnostika und screening-agenzien bei inflammatorischen und immunerkrankungen | |
CN110672855A (zh) | 肌动蛋白结合蛋白2筛选平滑肌功能障碍疾病治疗药物的用途 | |
US20230137756A1 (en) | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | |
TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
JP5051471B2 (ja) | 休止期脱毛症治療剤 | |
JP2024021165A (ja) | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するドライアイ治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170420 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180501 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190320 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190322 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190517 |